Targeted Oncology Staff

During a Targeted Oncology case-based roundtable event, Omid Hamid, MD, discussed the data supporting the use of hedgehog pathway inhibitors and immunotherapies for skin cancers.

During a Targeted Oncology case-based event, Alan H. Bryce, MD, discussed decision-making for treating a patient with non-metastatic castration-resistant prostate cancer.

During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discusses with participants the unexpected results of the LEAP-002 trial of lenvatinib plus pembrolizumab versus pembrolizumab alone for patients with hepatocellular carcinoma. This is the second of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Adam Binder, MD, discussed trials supporting triplet and quadruplet regimens along with autologous stem cell transplant.

During a Targeted Oncology case-based roundtable event, Randy F. Sweis, MD, discussed the results of the TIVO-3 trial of tivozanib. This is the second of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Jason Westin, MD, discussed recent clinical trial data for patients with relapsed/refractory diffuse B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Ravi Salgia, MD, PhD, discussed with participants their approach to molecular testing and treatment of a patient diagnosed with non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Pankit Vachhani, MD, discussed with participants how to assess risk and begin treatment for myelofibrosis. This is the second of 2 articles based on this event.

During a live virtual event, Ghassan K. Abou-Alfa, MD, discussed the results of the REFLECT trial of lenvatinib versus sorafenib and the LEAP-002 trial of lenvatinib/pembrolizumab versus lenvatinib in patients with hepatocellular carcinoma.

During a Targeted Oncology case-based roundtable event, Randy F. Sweis, MD, discussed with participants their experience with the tolerability of tivozanib for recurrent advanced renal cell carcinoma. This is the first of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Pankit Vachhani, MD, discussed with participants how they would diagnose a patient who potentially has primary myelofibrosis.

During a Targeted Oncology case-based roundtable event, Moshe Ornstein, MD, MA, discussed how to treat a patient with intermediate-risk renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Jeffrey Zonder, MD, discussed with participants the later-line therapy options for patients who have relapsed following several lines of treatment for multiple myeloma.

During a Targeted Oncology case-based roundtable discussion, Zofia Piotrowska, MD, MHS, discussed the data from clinical trials supporting mobocertinib and amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion mutation.

During a Targeted Oncology case-based roundtable event, Rachel C. Jankowitz, MD, discusses the result of treatment with sacituzumab govitecan in the ASCENT trial of patients with triple-negative breast cancer.

During a Targeted Oncology case-based roundtable event, Chad Hamilton, MD, broke down the data that shows how the use of PARP inhibition as a first-line maintenance therapy for patients with advanced ovarian cancer is impacting patients.

During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, discussed the data supporting the use of atezolizumab and durvalumab as therapy for patients with small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Pallawi Torka, MD, discussed with participants the use of novel therapies for patients with diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Robert J. Motzer, MD, discussed with participants their experiences using lenvatinib in treatment of advanced renal cell carcinoma. This is the second of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Rachel E. Sanborn, MD, discussed with participants the case of a patient with metastatic lung adenocarcinoma with potential targetable biomarkers.

During a Targeted Oncology case-based roundtable event, Jennifer M. Matro, MD, discussed the data supporting systemic therapies for treatment of early-stage HER2-positive breast cancer including trastuzumab and pertuzumab.

During a case-based roundtable event, Bhavana Pothuri, MD, discussed the use of PARP inhibitors to treat first-line advanced ovarian cancer.

During a live virtual event, John O. Mascarenhas, MD, discussed with participants the data supporting the use of pacritinib for patients with myelofibrosis. This is the second of 2 articles based on this event.

Peter Voorhees, MD, discussed managing adverse events related to belantamab mafadotin in patients with relapsed/refractory multiple myeloma during a live event.

During a case-based roundtable event, Ashley Evan Ross, MD, PhD, reviewing therapeutic options for a patient with metastatic hormone-sensitive prostate cancer.

Ellen K. Ritchie, MD, discuss the case of a 68-year-old man with high-risk myelofibrosis during a case-based roundtable event.

Mark A. Socinski, MD provides insight on biomarker testing to identify patients with NTRK gene fusion-positive non–small cell lung cancer.

During a case-based roundtable event, Christos Vaklavas, MD moderated a discussion about treatment option for a 48-year-old woman with triple negative breast cancer following adjuvant chemotherapy.

During a case-based roundtable event, Thomas Hutson, DO, PharmD, discussed challenges with treating a 59-year-old woman with clear cell renal cell carcinoma.

During a live virtual event, Edwin M. Posadas, MD, discussed the use of cabazitaxel in patients with metastatic castration-resistant prostate cancer with participants. This is the second of 2 articles based on this event.